St. Jude Medical has secured CE mark approval for magnetic resonance (MR) conditional labeling of its Quadra Allure MP cardiac resynchronization therapy pacemaker (CRT-P).
Featuring MultiPoint Pacing Technology, the Quadra Allure MP CRT-P offers patients the flexibility to undergo full-body diagnostic magnetic resonance imaging (MRI) scans of up to 1.5 Tesla for other conditions.
The Quadra Allure MP CRT-P with MRI labeling will work with Quarlet LV lead, which features four electrodes that allow to offer different pacing configurations to manage heart failure patients.
MultiPoint Pacing technology enables physicians to capture more left ventricular tissue quickly by delivering pacing pulses to multiple left ventricle locations rather than the traditional single pulse for each heartbeat.
The new Quadra Allure MP CRT-P with MRI labeling is also compatible with the SyncAV CRT software that adjusts pacing based on real-time changes in a patient’s cardiac condition.
It also helps physicians to improve treatment of patients who have responded positively to traditional CRT.
St. Jude Medical global research and development medical director and vice president Dr Philip Adamson said: “The Quadra Allure MP is the only CRT-P with MultiPoint Pacing technology, MRI full-body labeling, and more clinical options to treat patients who don’t respond to initial pacing therapy.
“This new technology allows patients who have heart failure that is challenging to manage to receive more effective therapy and still be able to get an MRI for other medical conditions if needed.”
Image: St. Jude Medical’s Quadra Allure MP CRT-P. Photo: courtesy of Business Wire.